Key words: Rheumatoid arthritis, combination drug therapy, methotrexate, disease-modifying anti-rheumatic drugs, immunosuppressive agents
نویسنده
چکیده
1Department of Internal Medicine I, 2Institute for Health Economics and Clinical Epidemiology, University Hospital of Cologne, Cologne. Germany. Thomas Rath, MD A. Rubbert, MD Please address correspondence to: Thomas Rath, MD, Department of Internal Medicine I, University Hospital of Cologne, Kerpener Straße 62, 50937 Cologne, Germany. E-mail: [email protected] Received and accepted on September 8, 2010. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S52-S57. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2010.
منابع مشابه
Bone mineral density changes during treatment of rheumatoid arthritis with disease-modifying-anti-rheumatic drugs
Background: Bone mineral density (BMD) changes during the course of rheumatoid arthritis (RA). The present study was designed to investigate the status of BMD in patients with RA treated with anti-rheumatic drugs. Methods: BMD at the femoral neck (FN-BMD) and lumbar spine (LS-BMD) were measured by dual energy x-ray absorptiometry (DXA) method using Norland densitometer. Disease activity (DA) wa...
متن کامل[A short history of anti-rheumatic therapy - VI. Rheumatoid arthritis drugs].
The treatment of rheumatoid arthritis traditionally includes symptomatic drugs, showing a prompt action on pain and inflammation, but without any influence on disease progression, and other drugs that could modify the disease course and occasionally induce clinical remission (DMARDs or disease modifying anti-rheumatic drugs). This review describes the historical steps that led to the use of the...
متن کاملAre biologics more effective than classical disease-modifying antirheumatic drugs?
Major achievements have been reached in the treatment of rheumatoid arthritis during past decades due to the recognition of methotrexate as an anchor drug for treatment of rheumatoid arthritis, due to the notion of a treatment window of opportunity in patients with recent-onset rheumatoid arthritis necessitating early aggressive therapy, due to the development of biologics and due to remission ...
متن کاملComparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
Biologic therapies in rheumatoid arthritis are now part of standard practice for disease that proves difficult to control with conventional disease-modifying anti-rheumatic drugs. While anti-tumor necrosis factor therapies have been commonly used, other targeted biologic therapies with different mechanisms of action are becoming increasingly available. Abatacept is a recombinant fusion protein ...
متن کاملMethotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
The two major advances over the 1990s in the treatment of rheumatoid arthritis (RA) were a shift in strategy from a "pyramid", in which disease modifying anti-rheumatic drugs (DMARDs) were deferred for several years, to the early aggressive use of DMARDs and widespread acceptance of methotrexate as the DMARD with the most long-term effectiveness and safety. Methotrexate courses are continued fa...
متن کامل